In comments to federal agency, PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for prescription medicines

In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to maximize profits, often in...
Read More
PhRMA presents research at ISPOR 2022

Last week at the ISPOR annual international meeting, PhRMA partnered with multiple organizations committed to advancing value assessment research and methods. We worked with a range of academics,...
Read More
Report finds PBMs are increasingly restricting patient access to medicines

More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report from Xcenda. The report is further evidence of...
Read More
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free

Recently, NBC News’ Today did a profile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). In April 2012, the...
Read More
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

In two years, biopharmaceutical companies have gone from zero to 13 billion COVID-19 vaccine doses produced. They’ve worked across the industry and on every continent to meet the global demand for...
Read More
The time is now to address Brazil’s notorious patent backlog

It has been widely acknowledged that long patent examination delays cripple innovation, hinder economies, impede job creation and frustrate the launch of new products. Increased patent review times...
Read More
Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

A new study from the Office of Health Economics (OHE) confirmed that the EQ-5D, a tool commonly used in health technology assessments (HTAs) often excludes outcomes important to patients and their...
Read More
Addressing social determinants of health to improve equitable access to medicines

PhRMA Awards $150,000 to Address Social Determinants of Health:Announcing the Recipients of Round 4 of the PhRMA Collaborative Actions to Reach Equity (CAREs) Grant Program As part of PhRMA’s...
Read More
Gene therapies can reduce treatment burden and costs for patients with blood disorders

A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...
Read More
Report: More than 500 medicines in development to treat disorders of the blood

Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...
Read More
A conversation with William Pao, Chief Development Officer of Pfizer

Our industry continues working to build a more resilient, affordable and equitable health care system. I recently had the opportunity to connect with William Pao, M.D., Ph.D., Chief Development...
Read More
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...
Read More
Why drug importation is bad for Americans

Drug importation schemes are dangerous and have significant negative consequences for both individuals and our health care system. Importation refers to when governments or individuals circumvent the...
Read More
Ensuring timely reauthorization of PDUFA and BsUFA

Today, the House Energy and Commerce Subcommittee on Health will be hosting a markup session on the comprehensive legislative package to reauthorize the human drug user fee programs, including the...
Read More
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

The COVID-19 pandemic has made clear how important a stable health care system is to the American people, both during times of crisis and beyond. Patients deserve sustainable, patient-centered...
Read More
During the pandemic, about four in 10 American adults have reported symptoms of anxiety or depressive disorder. This share is up from one in 10 adults reporting symptoms prior to the pandemic....
Read More
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data...
Read More
Study finds insurance barriers disproportionately burden patients with chronic illness

A recent Patient Experience Survey found that Americans with serious chronic conditions, including autoimmune diseases, mental health conditions and neurologic conditions were more likely than all...
Read More
A conversation with Barry Greene, CEO of Sage Therapeutics

Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA...
Read More
Innovative contracts continue to gain traction and improve quality of care

Innovative contracts can help bring more value to patients and the health care system. These types of payment arrangements can include:
Read More